Nile Therapeutics, Inc. (NASDAQ: NLTX)

Nile Therapeutics, Inc. (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, is focused on developing novel products designed to treat cardiovascular disease. CD-NP, the company’s lead compound, is a chimeric natriuretic peptide that is currently in clinical studies for an initial indication of acute decompensated heart failure. Additionally, the company is also developing CU-NP, a chimeric natriuretic peptide, and 2NTX-99, a small molecule with anti-atherothrombotic and nitric oxide donating properties. For further information, visit the Company’s web site at www.nilethera.com.